<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="which will contribute to the development of effective prevention and" exact="treatment" post="strategies. Hence, this review will focus on recent progress"/>
 <result pre="in SARS-CoV-2 to provide a framework for the prevention and" exact="treatment" post="of COVID-19. 2 Structure of SARS-CoV-2 The SARS-CoV-2 genome"/>
 <result pre="MERS-CoV are responsible for atypical pneumonia. The causes of different" exact="infection" post="sites are likely related to the presence of dipeptidyl"/>
 <result pre="[29]. Analysis of the first 99 confirmed cases of SARS-CoV-2" exact="infection" post="revealed that cytokine storm syndromes occurred in patients with"/>
 <result pre="function in SARS-CoV-2-infected patients. ARDS, decreased immune function and secondary" exact="infection" post="further worsens respiratory failure. 4 Epidemiological characteristics of SARS-CoV-2"/>
 <result pre="the disease was been confirmed to be an acute respiratory" exact="infection" post="caused by a novel CoV. To date, the number"/>
 <result pre="total of 80 304 confirmed cases of pneumonia with SARS-CoV-2" exact="infection" post="from 34 provinces (districts and cities). These included 6806"/>
 <result pre="tract is probably not the only route of transmission. Close" exact="contact" post="is also a source of transmission of SARS-CoV-2. For"/>
 <result pre="For example, SARS-CoV-2 can be transmitted through direct or indirect" exact="contact" post="with mucous membranes in the eyes, mouth or nose"/>
 <result pre="that the digestive tract is a potential route of SARS-CoV-2" exact="infection" post="besides the respiratory tract. However, additional studies are required"/>
 <result pre="of the first patient known to have died from SARS-CoV-2" exact="infection" post="[55]. Biopsy samples were obtained from lung tissue of"/>
 <result pre="are highly similar to those seen in SARS-CoV and MERS-CoV" exact="infection" post="[56,57]. Taken together, understanding the pathological characteristics of this"/>
 <result pre="may help physicians to formulate a timely strategy for the" exact="treatment" post="of similar severe patients and to decrease mortality. 4.9"/>
 <result pre="and pleural effusion. 4.10 Detection of SARS-CoV-2 Rapid and accurate" exact="detection" post="of SARS-CoV-2 is essential to control the outbreak of"/>
 <result pre="is essential to control the outbreak of COVID-19. Nucleic acid" exact="detection" post="is a major method of laboratory diagnosis. Reverse transcription"/>
 <result pre="diagnosis. Reverse transcription quantitative PCR (RT-qPCR) is a molecular biological" exact="diagnosis" post="technology based on nucleic acid sequences. The complete SARS-CoV-2"/>
 <result pre="collection of these specimen types by healthcare workers requires close" exact="contact" post="with patients, which poses a risk of spreading the"/>
 <result pre="is a promising non-invasive specimen type for diagnosis, monitoring and" exact="infection" post="control of COVID-19 patients. Besides RT-qPCR, Zhang et al."/>
 <result pre="CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter UnLOCKing) technique for the" exact="detection" post="of SARS-CoV-2 [63]. Using synthetic SARS-CoV-2 virus RNA fragments,"/>
 <result pre="with RT-qPCR, the SHERLOCK technique is more accurate and the" exact="detection" post="time is reduced by one-half. Thus, use of the"/>
 <result pre="by one-half. Thus, use of the SHERLOCK technique for the" exact="detection" post="of SARS-CoV-2 in clinical patient samples is expected. 5"/>
 <result pre="confirmed cases should be treated in designated hospitals with effective" exact="isolation" post="and protective conditions. Suspected cases should be treated in"/>
 <result pre="care unit as soon as possible. 5.1 General treatments General" exact="treatment" post="strategies include bed rest and supportive treatments, ensuring sufficient"/>
 <result pre="role in host resistance to viral infection. IFNα suppresses viral" exact="infection" post="by directly interfering with replication of the virus and"/>
 <result pre="has also been reported that cynomolgus monkeys are protected from" exact="infection" post="with SARS CoV by treatment with IFNα [66]. Moreover,"/>
 <result pre="cynomolgus monkeys are protected from infection with SARS CoV by" exact="treatment" post="with IFNα [66]. Moreover, the therapeutic benefit of synthetic"/>
 <result pre="of SARS-CoV-2. In addition, several lines of evidence showed that" exact="treatment" post="with lopinavir/ritonavir alone or in combination with other antiviral"/>
 <result pre="[74], [75], [76]. Thus, ribavirin could be considered as a" exact="treatment" post="option for COVID-19 patients. 5.2.4 Chloroquine Chloroquine is a"/>
 <result pre="5.2.5 Arbidol (umifenovir) Arbidol is an antiviral drug against influenza" exact="infection" post="that is widely used in Russia and China. Arbidol"/>
 <result pre="or combined with antiviral drugs produced certain benefits in the" exact="treatment" post="of COVID-19 pneumonia [81], [82], [83]. Currently, many randomised"/>
 <result pre="an in vitro study showed that remdesivir potently blocked SARS-CoV-2" exact="infection" post="at low-micromolar concentrations and showed a high selectivity index"/>
 <result pre="selectivity index [79]. In addition, the first case of SARS-CoV-2" exact="infection" post="in the USA was treated with intravenous remdesivir when"/>
 <result pre="condition deteriorated [41]. Although remdesivir has some benefits for the" exact="treatment" post="of COVID-19 pneumonia, randomised controlled trials are still required"/>
 <result pre="and safety. Taken together, these antiviral drugs may be promising" exact="treatment" post="options for the treatment of COVID-19. However, there are"/>
 <result pre="these antiviral drugs may be promising treatment options for the" exact="treatment" post="of COVID-19. However, there are also a few points"/>
 <result pre="allogeneic, off-the-shelf, umbilical cord blood-derived NK cell therapy, to the" exact="treatment" post="of the newly emerged SARS-CoV-2 infection [90]. Whilst developing"/>
 <result pre="cell therapy, to the treatment of the newly emerged SARS-CoV-2" exact="infection" post="[90]. Whilst developing new drugs, new vaccines or clinical"/>
 <result pre="enhance immunity is currently a very feasible strategy for the" exact="treatment" post="and prevention of COVID-19 pneumonia. 5.3.2 Mesenchymal stem cells"/>
 <result pre="are good sources of MSCs. Numerous studies have shown that" exact="treatment" post="with MSCs can ameliorate acute/chronic lung injury and ARDS"/>
 <result pre="number of SARS-CoV-infected patients in Taiwan and Hong Kong received" exact="treatment" post="with convalescent plasma during the early course of the"/>
 <result pre="convalescent plasma could, theoretically, be a promising option for the" exact="treatment" post="and prevention of SARS-CoV-2 infection, although this has not"/>
 <result pre="or in combination with other neutralising monoclonal antibodies, for the" exact="treatment" post="of COVID-19 pneumonia. 5.5 Chinese medicine Glycyrrhizin, an active"/>
 <result pre="the compound was reported to be clinically effective for the" exact="treatment" post="of SARS at that time [110,111]. Recently, glycyrrhizin was"/>
 <result pre="to have the potential to inhibit ACE2 and therefore block" exact="infection" post="with SARS-CoV-2 [112]. Baicalin, another traditional Chinese herbal medicine,"/>
 <result pre="antiviral activity against 10 clinical isolates of SARS-CoV by neutralisation" exact="tests" post="[114]. In addition, quercetin is a plant flavone that"/>
 <result pre="medicine also plays a key role in the prevention and" exact="treatment" post="of COVID-19 pneumonia. 6 Conclusion and future directions SARS-CoV"/>
 <result pre="global threat to health caused by SARS-CoV-2, effective prevention and" exact="treatment" post="of COVID-19 pneumonia will be urgently needed. However, the"/>
 <result pre="bat and human SARS-CoVs. A number of antiviral drugs and" exact="treatment" post="methods for SARS-CoV infection have also been considered for"/>
 <result pre="A number of antiviral drugs and treatment methods for SARS-CoV" exact="infection" post="have also been considered for the treatment and prevention"/>
 <result pre="methods for SARS-CoV infection have also been considered for the" exact="treatment" post="and prevention of COVID-19 pneumonia. We have been warned"/>
 <result pre="ChinaLancet395202049750610.1016/S0140-6736(20)30183-531986264 44ChenHGuoJWangCLuoFYuXZhangWClinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
 <result pre="management plan for prevention and control of 2019 novel coronavirus" exact="infection" post="(1st Edition) [in Chinese]Zhongguo Dang Dai Er Ke Za"/>
 <result pre="Saudi Arabia: a descriptive studyLancet Infect Dis13201375276110.1016/S1473-3099(13)70204-423891402 51RotheCSchunkMSothmannPBretzelGFroeschlGWallrauchCTransmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN Engl J Med382202097097110.1056/NEJMc200146832003551"/>
 <result pre="studyLancet Infect Dis13201375276110.1016/S1473-3099(13)70204-423891402 51RotheCSchunkMSothmannPBretzelGFroeschlGWallrauchCTransmission of 2019-nCoV infection from an asymptomatic" exact="contact" post="in GermanyN Engl J Med382202097097110.1056/NEJMc200146832003551 52QuiltyBJCliffordSFlascheSEggoRMcollab: CMMID nCoV Working"/>
 <result pre="Engl J Med382202097097110.1056/NEJMc200146832003551 52QuiltyBJCliffordSFlascheSEggoRMcollab: CMMID nCoV Working GroupEffectiveness of airport" exact="screening" post="at detecting travellers infected with novel coronavirus (2019-nCoV)Euro Surveill25202010.2807/1560-7917.ES.2020.25.5.2000080"/>
 <result pre="of a fatal case of Middle East respiratory syndrome coronavirus" exact="infection" post="in the United Arab Emirates, April 2014Am J Pathol186201665265810.1016/j.ajpath.2015.10.02426857507"/>
 <result pre="of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREuro Surveill25202010.2807/1560-7917.ES.2020.25.3.2000045 61ChuDKWPanYChengSMSHuiKPYKrishnanPLiuYMolecular" exact="diagnosis" post="of a novel coronavirus (2019-nCoV) causing an outbreak of"/>
 <result pre="coronavirus (2019-nCoV) causing an outbreak of pneumoniaClin Chem66202054955532031583 62ToKKTsangOTChik-Yan YipCChanKHWuTCChanJMCConsistent" exact="detection" post="of 2019 novel coronavirus in salivaClin Infect Dis2020 Feb"/>
 <result pre="print] 63Zhang F, Abudayyeh OO, Gootenberg JS. A protocol for" exact="detection" post="of COVID-19 using CRISPR diagnostics. https://broad.io/sherlockprotocol[accessed 1 April 2020]."/>
 <result pre="of the antiviral effects of interferon-α against a SARS-like coronavirus" exact="infection" post="in vitroCell Res16200622022910.1038/sj.cr.731003016474437 66HaagmansBLKuikenTMartinaBEFouchierRARimmelzwaanGFvan AmerongenGPegylated interferon-α protects type 1"/>
 <result pre="66HaagmansBLKuikenTMartinaBEFouchierRARimmelzwaanGFvan AmerongenGPegylated interferon-α protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaquesNat Med10200429029310.1038/nm100114981511 67LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHInterferon alfacon-1 plus corticosteroids in severe"/>
 <result pre="syndrome: a preliminary studyJAMA29020033222322810.1001/jama.290.24.322214693875 68WalmsleySBernsteinBKingMArribasJBeallGRuanePLopinavir–ritonavir versus nelfinavir for the initial" exact="treatment" post="of HIV infectionN Engl J Med34620022039204610.1056/NEJMoa01235412087139 69PulidoFArribasJRDelgadoRCabreroEGonzález-GarcíaJPérez-EliasMJLopinavir–ritonavir monotherapy versus"/>
 <result pre="pneumonia coronavirus proteasesbioRxiv2020 Feb 310.1101/2020.01.31.929695 71ChuCMChengVCHungIFWongMMChanKHChanKSRole of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 72SheahanTPSimsACLeistSRSchäferAWonJBrownAJComparative therapeutic"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res23201330030210.1038/cr.2012.16523208422 79WangMCaoRZhangLYangXLiuJXuMRemdesivir and chloroquine effectively"/>
 <result pre="China: retrospective case seriesBMJ202010.1136/bmj.m606368m606 84de WitEFeldmannFCroninJJordanROkumuraAThomasTProphylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc Natl"/>
 <result pre="basis for the recognition of herpes simplex virus type 1" exact="infection" post="by human natural killer cellsFront Immunol9201818310.3389/fimmu.2018.0018329483911 88AraseHMocarskiESCampbellAEHillABLanierLLDirect recognition of"/>
 <result pre="MeulenJBakkerABvan den BrinkENWeverlingGJMartinaBEHaagmansBLHuman monoclonal antibody as prophylaxis for SARS coronavirus" exact="infection" post="in ferretsLancet36320042139214110.1016/S0140-6736(04)16506-915220038 104ter MeulenJvan den BrinkENPoonLLMarissenWELeungCSCoxFHuman monoclonal antibody combination"/>
</results>
